Advantage Alpha Capital Partners LP Has $6.40 Million Position in Stevanato Group S.p.A. (NYSE:STVN)

Advantage Alpha Capital Partners LP grew its stake in Stevanato Group S.p.A. (NYSE:STVN - Free Report) by 27.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 293,865 shares of the company's stock after purchasing an additional 63,041 shares during the quarter. Stevanato Group makes up approximately 1.5% of Advantage Alpha Capital Partners LP's investment portfolio, making the stock its 20th largest holding. Advantage Alpha Capital Partners LP owned approximately 0.10% of Stevanato Group worth $6,403,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Natixis Advisors LLC grew its stake in Stevanato Group by 20.3% in the 3rd quarter. Natixis Advisors LLC now owns 51,343 shares of the company's stock valued at $1,027,000 after buying an additional 8,669 shares during the last quarter. Raymond James Trust N.A. boosted its holdings in shares of Stevanato Group by 22.6% during the third quarter. Raymond James Trust N.A. now owns 12,556 shares of the company's stock worth $251,000 after acquiring an additional 2,317 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of Stevanato Group by 16.9% in the third quarter. The Manufacturers Life Insurance Company now owns 294,235 shares of the company's stock valued at $5,885,000 after purchasing an additional 42,629 shares during the last quarter. Hardy Reed LLC grew its position in shares of Stevanato Group by 8.2% in the third quarter. Hardy Reed LLC now owns 11,077 shares of the company's stock valued at $222,000 after purchasing an additional 840 shares during the last quarter. Finally, Glenmede Trust Co. NA increased its stake in shares of Stevanato Group by 12.7% during the third quarter. Glenmede Trust Co. NA now owns 35,941 shares of the company's stock worth $719,000 after purchasing an additional 4,050 shares during the period.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on STVN. Bank of America boosted their price target on Stevanato Group from $24.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, December 13th. UBS Group reduced their target price on shares of Stevanato Group from $24.00 to $23.50 and set a "neutral" rating for the company in a research report on Friday, March 7th. Wolfe Research started coverage on shares of Stevanato Group in a research report on Friday, December 13th. They set an "outperform" rating and a $28.00 price target on the stock. Morgan Stanley reissued an "equal weight" rating and issued a $23.00 price objective (down previously from $24.00) on shares of Stevanato Group in a report on Tuesday, December 3rd. Finally, William Blair reaffirmed an "outperform" rating on shares of Stevanato Group in a report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of €25.70 ($27.93).

Stevanato Group Price Performance

STVN traded down €0.07 ($0.08) on Friday, hitting €20.25 ($22.01). 209,100 shares of the stock were exchanged, compared to its average volume of 347,647. The firm has a market capitalization of $6.13 billion, a price-to-earnings ratio of 43.09, a PEG ratio of 7.18 and a beta of 0.60. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. Stevanato Group S.p.A. has a 12 month low of €16.56 ($18.00) and a 12 month high of €32.98 ($35.85). The business has a 50-day moving average of €20.90 and a two-hundred day moving average of €20.59.

Stevanato Group (NYSE:STVN - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share for the quarter, hitting the consensus estimate of €0.20 ($0.22). Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. The business had revenue of €352.68 million during the quarter, compared to the consensus estimate of €346.26 million. Sell-side analysts forecast that Stevanato Group S.p.A. will post 0.5 EPS for the current fiscal year.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.